Related Experiment Video

Updated: Jun 12, 2025

Establishing a Silicosis Rat Model via Exposure of Whole-Body to Respirable Silica
05:03

Establishing a Silicosis Rat Model via Exposure of Whole-Body to Respirable Silica

Published on: October 28, 2022

1.2K

Cardamonin inhibits silicosis development through the PI3K-AKT signaling pathway

Zhimin Ye1, Zhiyuan Niu2, Juan Li2

  • 1Department of pathology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China; Department of Pathology, Basic Medical School, Central South University, Changsha, Hunan 410013, China; Department of pathology, Xiangya Hospital, Central South University, Changsha 410008, China.

Ecotoxicology and Environmental Safety
|September 22, 2024
PubMed

Insights

Cardamonin (CDM) effectively inhibits silicosis progression by reducing lung fibrosis and fibroblast activation. This study reveals CDM

Area of Science:

  • Occupational Medicine
  • Pulmonary Fibrosis Research
  • Pharmacology

Background:

  • Silicosis is a severe occupational lung disease with limited treatment options.
  • Fibrosis, characterized by inflammation and fibroblast activation, is a key feature of silicosis.
  • Cardamonin (CDM) exhibits known anti-inflammatory and anti-fibrotic properties.

Purpose of the Study:

  • To investigate the antifibrotic effects of Cardamonin (CDM) on silicosis.
  • To elucidate the molecular mechanisms underlying CDM's action in silicosis.
  • To evaluate CDM as a potential therapeutic agent for silicosis.

Main Methods:

  • Established a silica (SiO2-M) stimulated fibroblast cell model.
  • Utilized Western Blot (WB), RT-qPCR, and immunofluorescence for molecular analysis.
  • Developed a silicosis mouse model via intratracheal silica suspension injection.
  • Performed RNA sequencing to identify signaling pathways involved.

Main Results:

  • CDM significantly inhibited SiO2-M-induced fibroblast activation, proliferation, and migration in vitro.
  • In vivo studies demonstrated that CDM retarded the progression of pulmonary fibrosis in a silicosis mouse model.
  • RNA sequencing suggested the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling pathway mediates CDM's antifibrotic effects.

Conclusions:

  • Cardamonin (CDM) demonstrates significant antifibrotic effects against silicosis.
  • The therapeutic potential of CDM in silicosis is linked to its modulation of the PI3K/AKT signaling pathway.
  • CDM offers a promising avenue for developing novel drug treatments for silicosis.

Keywords:
CardamoninFibroblastMacrophageMyofibroblastPI3K-AKTSilicosis

More Related Videos

A Silicosis Mouse Model Established by Repeated Inhalation of Crystalline Silica Dust10:45

A Silicosis Mouse Model Established by Repeated Inhalation of Crystalline Silica Dust

Published on: January 6, 2023

2.2K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

351

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178